New Hungary office: Honoring heritage while looking forward

Earlier this year, we celebrated the opening of our 15th office worldwide in Szeged, Hungary – a community with a long history of resilience and rebirth on the world stage. We wanted to share the journey to Szeged through the eyes of Zsófia Székács-Pecze, who led the site selection and renovation process on behalf of Envision Pharma Group.

Click the button below to read Zsófia's blog post!

Close

Technology-enabled scientific communications company Envision Pharma Group (“Envision” or the “Company”) today announced Library, Datavision, and Scientific Communication Platform (SCP) modules will now feature Smart Citations from scite, an award-winning tool that helps students and researchers discover and understand research findings better.

Fully integrated into the publication details held within Library, Datavision, and SCP modules, Smart Citation badges provide regularly updated, at-a-glance views of how research has been cited and permits click-through access to the scite website for more detailed information on the article. This new functionality sits alongside and enhances the existing article-level metrics provided in iEnvision through integrations with Altmetric and Scopus.

Russell Traynor, Envision’s Global Head, iEnvision Platform Strategy, and former chair of the International Society of Medical Publication Professionals, said, “We are excited to announce this collaboration and hope that the addition of Smart Citations to Library, Datavision, and SCP will provide additional insights and value to the users of our solutions.”

Dr. Josh Nicholson, Chief Executive Officer of scite, added, “We’re very happy to be working with Envision to provide a powerful integration between the two platforms. Smart Citations are already used by various pharmaceutical companies and communications agencies and we’re happy to surface them in Library for a more streamlined workflow.”

About Envision Pharma Group

Founded in 2001, Envision Pharma Group is a global, technology-enabled scientific communications company serving pharmaceutical, biotechnology, and medical device companies. As a leading provider of evidence-based communication services and industry-leading technology solutions (iEnvision) that have applicability across many areas of medical affairs and related functional responsibility, Envision provides scientific communication services and technology solutions to more than 90 companies, including 19 of the top 20 pharmaceutical companies. Learn more at: www.envisionpharmagroup.com

About scite

scite is a Brooklyn-based start-up that helps researchers discover and evaluate scientific articles better through Smart Citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by researchers from around the world and is funded in part by the National Science Foundation and the National Institute of Drug Abuse of the National Institutes of Health. Learn more at: scite.ai

About iEnvision Library

Library, built on the iEnvision medical project management platform, serves as a central repository for the enterprise-wide storage and sharing of final, approved scientific and medical materials such as publications and slide decks. Embedding Smart Citation in Library allows an at-a-glance view of the total number of times a paper has been cited and the context of these citations. Learn more at: www.envisionpharmagroup.com/technology/ienvision-library

About iEnvision Datavision®

The iEnvision Datavision module is designed to drive the compliant and efficient management of scientific and medical publications. With role-specific dashboards, publication managers can access the detailed information needed to start and manage publications. Containing built-in checklists and system validation, it ensures publications comply with Good Publication Practice and the International Committee of Medical Journal Editors (ICMJE) requirements. Learn more at: www.envisionpharmagroup.com/technology/datavision

About iEnvision Scientific Communication Platform

iEnvision’s SCP is a centralized medical affairs solution, linking key scientific themes and statements to product-related assets such as publications, slides, and videos. The common template of SCP themes, key statements, and supporting statements maintains simple user navigation and a standardized approach to the formatting and development of SCPs – with a lexicon designed to ensure a consistent use of language that includes preferred and prohibited terms. Learn more at: www.envisionpharmagroup.com/technology/scientific-communication-platform-module

Close

Leading global technology-enabled scientific communications company Envision Pharma Group has launched a suite of behavioral science-led solutions to expand the group’s capabilities and optimize value offering to its clients.

Envision the Change is spearheaded by Mark Lakeram (Global Lead, Behavioral Science) and supported by Directors Jenny Squibbs (in the UK) and Justine Swann (in the US). As a dedicated team of behavioral scientists, they understand that to affect real change the intricacies and realities of everyday life and health need to be considered.

Lakeram said, “All healthcare decisions are influenced by human behavior. By taking into account the science behind this, our proprietary Feel-Think-Do^TM model helps to decode why people make the decisions they do. From strategic and tactical planning, to aiding information recall through data visualization and adult learning techniques – we provide counsel and support to drive behavior change that ultimately improves health outcomes.”

Susanne Clark, Head of Envision Scientific Solutions, added, “No matter what product challenges are ahead, understanding the behavior of key stakeholders will be paramount. I’m delighted that we’ve strengthened our service offering with Envision the Change in order to support our clients across all aspects of medical affairs and marketing, from planning to creative implementation for both external and internal audiences.”

Close

Technology-enabled scientific communications company Envision Pharma Group (“Envision” or the “Company”) has announced a partnership with Vitaccess, an innovative research organization.

The Envision and Vitaccess partnership will bring a full-service, customizable approach to data gathering, insight generation, and scientific communications that will stand up to the nuances, scale, and challenges of any client setting.

Acknowledging that every client need is unique, this collaboration will help leverage patient-centric digital solutions to gather data quickly, flexibly, and at scale, and incorporate patients’ “lived experience” – insights which are often insufficiently integrated into the design and implementation of many RWE studies published globally.

The complexities in bringing a product to market cannot be underestimated. An increasing requirement for data leads to a growing need for more adaptive RWE research to be generated and communicated to regulators, pre and post approval. Envision and Vitaccess understand these additional demands placed on their biopharma clients, and the need to maximize value and access to their products through timely, insightful evidence generation which communicates the real-world impact of diseases and their treatments on patients.

Paul Archer, Envision Chief Commercial Strategy Officer, said, “This collaboration offers clients a really powerful toolbox to accelerate, scale, and publish their evidence-generation activities. We admire Vitaccess’ innovative, inclusive digital approach to designing patient-centric RWE studies, and whose flexible solutions provide access to outcomes measures that serve regulators, payers, and health systems all over the world.”

Dr. Mark Larkin, CEO and Founder of Vitaccess, commented, “Combining our Vitaccess Real™ real-time RWE platform and expertise in patient-centric research with Envision’s established leadership in medical affairs and communications brings clients a unique, full-service offering for engaging with patients and caregivers globally.”

Close

Leading global technology-enabled scientific communications company Envision Pharma Group has promoted Paul Archer to Chief Commercial Strategy Officer (CCSO).

In his new role, Archer will lead the development of an integrated commercial group strategy to drive continued revenue growth through service synergies and the implementation of new services. This is a newly defined position that reflects the continued expansion of Envision and its goals of being the global medical affairs partner of choice and to transform the pharma industry, ultimately leading to life-changing outcomes.

Working across the group, Archer will leverage Envision’s unique combination of technology and service capabilities to meet the evolving needs of its medical affairs clients and ensure it continues to lead the way in bringing innovative solutions to the market.

On his appointment that also sees Archer join Envision’s Executive Leadership Team, he said, “I am thrilled to be taking on this role. Envision is full of purpose-driven, talented people who thrive on delivering impactful, often award-winning work for our clients and their patients. I am genuinely excited to be able to apply my 20 years of strategic and commercial experience to drive a successful integrated commercial group for Envision and to realize the opportunities and value this creates for our clients, patients, talent, and Envision as a whole.”

David Thompson, CEO, Envision Pharma Group, added, “Paul has been a strong addition to Envision since he joined a year ago, and he will now lead a growing mandate as Chief Commercial Strategy Officer as we continue to exploit synergies across our four verticals of scientific services, technology, emerging biotech, and value – as well as uncover new service offerings through investment and acquisition that can help us improve our partnership strength with clients.”

Close

Leading global technology-enabled scientific communications company Envision Pharma Group has appointed Julie Beeso as its Global Director, Professional Development and Engagement.

Having worked for almost 25 years across different medical communications roles in the UK and US, Julie’s extensive expertise will be used to develop, communicate, and execute a comprehensive professional development and talent management strategy for Envision Scientific Solutions (ESS) that supports progressive programs and engagement.

Starting out as a writer, Julie advanced to facilitating the account direction and team leadership for blockbuster launches in a previous role; overseeing new business activities; heading up a company division, and establishing a New York office. Julie joins Envision from Oxford PharmaGenesis where she helped to set up and lead its patient engagement specialty while also focusing on company-wide quality and training activities.

Alongside continuing to teach people how to be the best they can be in a competitive medcomms landscape, Julie’s responsibilities will cover ESS engagement and relations, talent placement and retention, alternative resourcing, and overseeing performance management.

Julie said, “I feel privileged to have the opportunity to work for Envision, whose reputation for integrity and quality – always alongside technological innovation – is second to none. Envision excels through its talented people. The company’s commitment to developing this talent is dynamic and inspiring, and I can’t wait to help take it to the next level!”

Susanne Clark, Global Head, Envision Scientific Services added, “We are thrilled to have Julie Beeso joining the team. With deep market insight and a unique skill set, Julie is ideally placed to meet the needs of a complex and rapidly evolving talent market. At Envision we have grown through continual innovation and improvement, and Julie will begin by scaling up our successful New Medical Writer program and elevating our entry talent offering. We are excited by this new chapter in our talent story.”

Close

Two Labs, an industry-leading pharma services company and part of Envision Pharma Group, today announced that it has acquired Riparian, a pharma consulting and SaaS company that helps manufacturers navigate pricing regulations, reporting, strategies, and program operations.

The acquisition expands Two Labs’ suite of pharma services, allowing the company to provide greater insights around the financials associated with launching and managing a drug, better positioning manufacturers for long-term success. Riparian’s deep understanding of government pricing regulations and program operations – combined with their consulting, business process outsourcing, and software capabilities – enables clients to better understand the financials of their drug, ensuring the prices reported to the government are in compliance with current government statutes and regulations.

“Government regulations and reporting requirements are growing increasingly complicated and it’s vital for both emerging and established manufacturers to work with an expert partner during this process,” said Howard Miller, CEO, Two Labs. “Riparian is a quickly growing, innovative company backed by a team of leading industry experts. It’s a privilege to have been selected as their partner by their leadership team.”

Riparian and Two Labs will work together to accelerate parent company, Envision Pharma Group’s US expansion plans in the emerging biotech pharma market. Envision acquired Two Labs in November 2020.

“This acquisition solidifies our vision to add Two Labs to the Envision family,” said David Thompson, CEO of Envision Pharma Group. “Bringing together Two Labs and Riparian reinforces Envision’s mission to invest in truly transformative organizations, and further expands our capabilities in improving patient access to life-changing medicines.”

“Like Two Labs, we’re committed to staying at the forefront of the evolving healthcare market, and we are excited for the growth we can experience by incorporating additional services and subject-matter expertise to meet evolving client needs,” said Riparian Co-Founder and CEO, David Chan. “This partnership elevates the work of both Two Labs and Riparian and creates significant growth potential.”

Riparian will continue operating out of their existing headquarters in Henderson, NV, with offices in Pasadena, CA and Johnson City, TN. Co-founders David Chan and Cynthia Hwang will remain with the company.

Close

Envision Pharma Group (“Envision” or the “Company”), a leading global technology-enabled scientific communications company, is pleased to announce the acquisition of doDOC Corp., a leader in document collaborative review, editing, and authoring.

doDOC is an innovative, best-in-class, Software as a Service (SaaS)-based platform that enables simultaneous collaboration in the review, editing, and authoring of documents among multiple users. Designed for the pharma and life sciences industries, it offers significant industry-specific advantages over general document authoring solutions in the market today.

While customers will have the choice to deploy doDOC standalone, the solution will be seamlessly integrated with Envision’s leading medical affairs platform, iEnvision. This unlocks the huge potential for customers to allow real time in-line editing of medical affairs documents, delivering efficiency gains of around 70% versus document processes without doDOC.

Founded in 2015 in Boston, MA, with a European base in Coimbra, Portugal, the company will operate as a business unit under its current brand and will continue to be led by doDOC CEO and co-founder, Federico Cismondi.

David Thompson, CEO, Envision, said, “Bringing doDOC into the Envision family enables us to continue to increase our innovative technology offerings to support life science companies’ goals in becoming ever more efficient and effective in the communication of key scientific data. doDOC is the standout company in its field and, critically, shares our values and commitment to working collaboratively to provide smart solutions that ensure our clients’ success. It will also allow us to consider developing capabilities that enable us to spread beyond our medical affairs client base, including supporting client commercial activities.”

“Envision’s acquisition of doDOC is great for our customers and employees. It allows doDOC to join a proven medical affairs technology leader and advance our solutions for the industry,” said Federico Cismondi, CEO, doDOC. “Most importantly, our companies share a commitment to provide industry-leading innovate solutions and to work together in a collaborative way to ensure our customers’ success.”

Manish Goel, Global Head of Envision Technology Solutions, added, “With our first clients now live on an integrated doDOC and iEnvision platform, we have a capability that no one else in the market can credibly claim as part of their solution. With doDOC as part of Envision Pharma Group, we can broaden our technology capabilities, creating efficiencies for clients and adding value as a strategic partner to deepen our client relationships.”

Close

Envision Pharma Group (“Envision” or the “Company”), a leading global technology-enabled scientific communications company, is pleased to announce the acquisition of Two Labs, an industry-leading provider of integrated and customized commercial solutions to the pharmaceutical and biotechnology sector.

• Two Labs brings market-leading commercialization, strategic consulting, market access, and market intelligence solutions that span the full product life cycle
• Move builds on Envision’s established leadership position as the preferred tech-enabled scientific communications company for medical affairs, while deepening its presence in the critical US domestic market, and with small and midsize biopharma clients
• Group to deliver customized “launch excellence” offering, becoming a global go-to strategic partner for pharma in medical affairs, healthcare communications, and consulting services –charting the path from clinical to commercial for a new product, and guiding clients on the optimum journey

The combined company will bring together complementary clients, services, and technologies, extending Envision’s scientific footprint to new clients in the “product pre-launch setting” – while opening up new business avenues and geographies for Two Lab’s best-in-class launch planning services.

Two Labs, founded in 2003 and headquartered in Powell, Ohio, has offices and operations across the US and UK, and is an established strategic consulting and commercialization provider to the biopharma industry. Two Labs helps pharmaceutical companies develop and execute customized launch strategies for products. It has a proven track record of successful launches across all major therapeutic areas with unmatched client satisfaction.

Envision’s acquisition of Two Labs follows the recent announcement of GHO Capital’s increased investment in the company and the backing of management for its continued global expansion. Since being founded in 2001, Envision has delivered strong year-on-year organic growth and established leadership in medical affairs strategy, medical communications, and enterprise-wide iEnvision® technology. A number of strategic acquisitions in medical strategy, Health Economics and Market Access (HEMA), and behavioral science-led communications have played an important role in its expansion.

David Thompson, CEO, Envision, said, “This exciting combination of Envision and Two Labs creates a compelling and unrivaled proposition in launch excellence partnership globally and in the US. We look forward to sharing our joint expertise and leveraging our complementary services across medical affairs and product launch planning to support our clients in their goal of bringing new medicines to market effectively and compliantly, to improve patient outcomes.”

Howard Miller, CEO, Two Labs, added, “We are delighted to be joining the Envision family and taking Two Labs to the next logical step in its successful journey to date. With Envision’s global footprint and Two Labs’ market-leading US footprint, we have a unique opportunity to enrich our client partnerships with more connected services across the launch continuum. The cultural fit between our organizations is compelling, and we look forward to a new chapter for Two Labs in partnering with David and the Envision team.”

The Partners at GHO commented, “We are glad to welcome Howard and the Two Labs team to the Envision Group. They have built a market-leading strategic consulting and commercialization business that in combination with Envision’s position as the ‘go-to’ tech-enabled scientific communications company will deliver major value to global pharma and biotech through a combined, unique launch excellence offering that accelerates and improves their route to market.”

Excellere Partners, a US-based private equity firm focused on partnering with entrepreneurs and management teams in emerging growth companies, will exit its investment in Two Labs following a successful 4-year partnership.

Close

Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, together with the existing Envision management team and employees, have increased their investment in Envision Pharma Group (“Envision” or the “Company”), a leading technology-enabled scientific communications company.

The transaction sees GHO lead a consortium of its investors headed by Mubadala Investment Company, and including HarbourVest Partners and Northwestern Mutual to drive a new phase of growth, while Ardian exits its investment following a successful 4-year partnership with Envision and GHO.

Founded in 2001, Envision helps biopharmaceutical and medical device companies commercialize new compounds through medical strategy, strategic publications planning, and medical communications delivery. Its flagship technology iEnvision^® – a global medical affairs platform, supports medical strategy, scientific communications internal/external research, and grant/request management activities to help pharmaceutical companies operate their businesses compliantly.

Over the last 19 years Envision has enjoyed outstanding year-on-year organic growth, with expansion supplemented via a number of key strategic acquisitions in medical strategy, Health Economics and Market Access (HEMA), and behavioral science-led communications. Consequently, Envision’s global reach now extends to Australia, Japan, Serbia, and Hungary, with the company employing over 800 people across 14 offices.

Having partnered with Envision for 4 years, GHO has a unique view of the business and its growth trajectory and is backing the management for continued expansion. Envision will pursue significant rollout of its iEnvision technology to widen its suite of platform solutions and strategic communications capabilities, and expects to see increased synergy between these two elements.

With acquisitions likely to play an important role toward facilitating the delivery of a deeper, more diversified service offering to global clients, Envision is set to enhance its position as the leading strategic medical affairs partner to the pharmaceutical industry.

David Thompson, CEO, Envision, said, “Having worked alongside GHO for 4 years, we are delighted they have chosen to extend and deepen the partnership in a new investment cycle. We see a clear commitment to expanding our reach across the healthcare services spectrum, most notably in medical affairs, with the ultimate goal of enhancing physicians’ abilities to improve patient outcomes.”

The Partners at GHO Capital commented, “We are delighted to continue our successful partnership with David and his management team. Envision is a company we know well and continue to believe in owing to its unique services and technology proposition. We look forward to supporting this ambitious team on their next phase of growth and in delivering Envision’s full potential as the go-to strategic partner in outsourced medical affairs, communications, and consulting services.”

Brian Hepburn, Co-Chairman and Founder, Envision, added, “For GHO Capital to take the majority shareholding in Envision speaks volumes in terms of its belief in our business and vision. We will be partnering with a team who already has a deep understanding of both the healthcare sector and our business, who know and respect the leadership team, and can positively contribute to our new 5-year business plan.”

Bruno Ladriere, Managing Director of Ardian Buyout in the UK, said, “Over the last 4 years, we have worked successfully with the Envision management and GHO to support the company’s growth, adding new service lines via acquisitions to increase the value brought to its clients. This first investment of our Buyout team in the UK has been a great success. We are confident the next phase of the Envision story will continue to demonstrate the company’s standing as the trusted partner of choice for medical affairs to the pharmaceutical industry.”

Close

The PM Society Digital Awards 2020 saw Envision pick up two Silver awards for Congress, Meetings & Events and for Innovation – Creativity as a result of its “See through diabetes” work in collaboration with Mundipharma.

Multichannel Director at Envision, Alex Watson, said, “These two Silver awards are another fantastic accolade for Envision. Following our success at the PM Society Awards in 2019, this really is testament to the excellence and consistency that our creative/digital team achieve. Congratulations to our exceptionally talented team that, in close partnership with Mundipharma and supported by Woolley Pau, conceptualized this novel and impactful way to engage a larger audience with this important and valuable message.”

Nick Morgan, Head of Specialist Driven Primary Care, Europe, Mundipharma, added, “We are thrilled that Mundipharma has been recognized for digital excellence in communicating this important message that will help to positively impact the lives of Type 2 Diabetes (T2D) patients everywhere. We put healthcare professionals and the patients they serve at the heart of everything we do, and to be recognized at the PM Society Digital Awards for this project is testament to this. Working with the Envision team to achieve these goals is a true partnership, where our objectives and vision meet the creativity and know-how to produce these exceptional results.”

2020 marks the eleventh year of the PM Society Digital Awards, where the best in digital creativity, innovation, and effectiveness are recognized from across the healthcare industry. The event prides itself on highlighting the best programs, tools, and campaigns across a broad range of digital activities.

Watson also noted, “Digital excellence is not just about employing the latest technology, but ensuring technological solutions support the creative proposition and aid in achieving the core communication objectives.”

Close

Global healthcare communications consultancy 90TEN, part of the Envision Pharma Group, was last night named Healthcare PR Consultancy of the Year at the SABRE Awards EMEA 2020.

Commenting on the award win, Paul Tanner, Global Head, 90TEN said, “2019 was 90TEN’s most successful year to date, driven by further investment in our team and the continued adoption of the company’s behavioral science-led communications services by clients. It’s terrific to see our ongoing expansion and to receive recognition for this across the EMEA region. This award is a reflection of the dedication of our incredible team and clients, who are passionate about making a difference through life-changing work.”

The consultancy was also a finalist for the Best Digital Campaign category for its “HIV Garage” program for Gilead Sciences.

The SABRE Awards are the world’s largest PR awards program, recognizing superior achievement in branding and reputation in North America, EMEA, Asia-Pacific, Latin America, South Asia, and Africa. The awards are delivered by PRovoke Media, the authoritative voice of the global public relations industry.

Close